Le Lézard
Classified in: Health
Subjects: SVY, TRI, SCZ

Young Blood Plasma Parkinson's Disease Investigation Six-Month Results Show Dramatic Improvements In Motor Symptoms and Mentation, Behavior and Mood


HOUSTON, Aug. 7, 2019 /PRNewswire/ -- The Neurology Center, a medical group practice of top doctors devoted to excellence in care, located in Houston, Texas, working in conjunction with two leading neurology and anti-aging specialists, has made available the concluding six-month results of their randomized controlled investigation of intravenously administering NuPlasma® young blood plasma into eighteen Parkinson's disease patients (8 NuPlasma - 10 Placebo).

In a landmark investigation that addresses a well-known neurological disorder that affects more than 10 million people worldwide, for which there has been previously no known treatment that can slow the progression of the disease and available drugs can only relieve symptoms, the randomized double-blind, placebo-controlled investigation, designed to evaluate the efficacy of 25 ml/kg intravenous NuPlasma young Fresh Frozen Plasma (yFFP®) administered in two doses over three days, continues to realize dramatic and statistically significant improvements.

Ultimately, for patients treated with yFFP, there were a number of Motor Symptom reductions observed during in-person neurologist-assessments at 6 months, including action tremor (-80.6), tremor at rest (-50.8%) and a number of instances of improved bradykinesia, including postural stability (-62.5%) and body bradykinesia (-25%).

With regard to Mentation, Behavior, and Mood, patients treated with NuPlasma yFFP experienced reductions in depression (-77.5%), motivation and initiative (-43.8%), and intellectual impairment (-38.9%). NuPlasma recipients also saw improvements in sensory complaints (-67.86%), handwriting (-34.9%) and swallowing (-32.5%).

With all patients continuing to be maintained on their pre-investigation treatments, after twenty-four weeks this newly collected data takes the investigation far past the point of where the yFFP is still in circulation, yet continues to show a prolonged residual benefit.

"It has been a privilege to observe and present the results of this yFFP investigation," stated Dr. Dian Ginsberg, MD, FAARM. "Parkinson's disease is one of a larger group of neurological conditions called motor system disorders and prior to making public these results from young blood plasma infusions, no available medications reversed the progression of the disease.  Young blood plasma infusions have now conclusively shown a lasting and unprecedented success in broadly improving patient outcomes.  It is with great encouragement that we believe the combination of microbiome correction, inflammation reduction and infusions of yFFP can mediate neurodegeneration in a significant and meaningful way."

Full study disease assessment and blood laboratory data is accessible online at:  www.youngplasmastudy.com.

About NuPlasma - NuPlasma is an accredited Blood Bank operating under FDA, AABB and CLIA's Good Manufacturing Practice regulations.  Located in San Marcos, Texas, NuPlasma is the world's first blood bank to collect young plasma exclusively from volunteer 18 ? 25 year old donors.  NuPlasma is dedicated to Making Lives Better® by providing physicians with exceptional quality, selection and service.

*The use of blood and blood products such as plasma in the United States is restricted only to the issuance of a prescription by a licensed physician.

Media Contact:
Young Plasma Study
281 569-4289
219501@email4pr.com 

SOURCE The Neurology Center


These press releases may also interest you

at 08:59
Focus Laboratories expands their business, making their one of a kind O3+Maquitm supplements available for purchase through Amazon.com. Focus Labs started in 2005 intending to create products geared towards promoting better ocular health. Focus Labs...

at 08:45
The Supreme Cannabis Company, Inc. ("Supreme Cannabis" or the "Company") (FRA: 53S1) today announced that Navdeep Dhaliwal resigned his seat on the Board of directors (the "Board") effective June 30, 2020. As previously announced on April 27, 2020,...

at 08:33
FORT LAUDERDALE, Fla., July 3, 2020 /PR Newswire/ -- Focus Laboratories plans to expand the reach of their supplement sales, following a successful return from the historic all-virtual ECRM conference. The Efficient Collaborative Retail Marketing...

at 08:32
Athletic Republic, the nation's leading sports performance training franchisor, today announced the rollout of its new partnership with Klean Athlete®, developer of premium nutritional supplements for athletes. Athletic Republic will be making the...

at 08:00
Gilead Sciences, Inc. today announced that the European Commission has granted conditional marketing authorization for Veklury® (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. The conditional marketing...

at 07:50
Mr. Clive J. Beddoe ("Mr. Beddoe") announces that he has acquired beneficial ownership of 9,177,782 common shares of SQI Diagnostics Inc. ("SQI") through the exercise of common share purchase warrants of SQI ("Warrants") for aggregate consideration...



News published on 7 august 2019 at 08:44 and distributed by: